1. Home
  2. GOVX vs SXTP Comparison

GOVX vs SXTP Comparison

Compare GOVX & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.59

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Logo 60 Degrees Pharmaceuticals Inc.

SXTP

60 Degrees Pharmaceuticals Inc.

HOLD

Current Price

$1.05

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOVX
SXTP
Founded
2001
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.6M
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
GOVX
SXTP
Price
$0.59
$1.05
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$1.00
$14.10
AVG Volume (30 Days)
584.9K
53.8K
Earning Date
04-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
36.77
EPS
N/A
N/A
Revenue
$2,489,145.00
$1,005,471.00
Revenue This Year
N/A
$33.92
Revenue Next Year
N/A
$51.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.49
52 Week Low
$0.12
$0.34
52 Week High
$4.40
$8.62

Technical Indicators

Market Signals
Indicator
GOVX
SXTP
Relative Strength Index (RSI) 37.87 35.17
Support Level $0.14 $0.45
Resistance Level $0.85 $1.12
Average True Range (ATR) 0.08 0.09
MACD 0.02 0.00
Stochastic Oscillator 7.63 4.00

Price Performance

Historical Comparison
GOVX
SXTP

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

About SXTP 60 Degrees Pharmaceuticals Inc.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Share on Social Networks: